LTR

Choose Selective LTR Inhibitors
Isoform-selective Inhibitors

LTR Products

  • All (6)
  • LTR Inhibitors (1)
  • LTR Antagonists (5)
  • New LTR Products
Catalog No. Product Name Information Product Use Citations Product Validations
S3998 (+)-α-Lipoic acid (+)-α-Lipoic acid ((R)-(+)-α-Lipoic acid, α-Lipoic acid, Alpha-Lipoic acid), a physiological form of thioctic acid, is a strong antioxidant that relieves diabetic neuropathic symptoms. It shows superior antioxidative effects to its racemate. R(+)-α-lipoic acid is an essential cofactor of mitochondrial enzyme complexes. R(+)-α-lipoic acid inhibits NF-κB-dependent HIV-1 LTR activation.
S1633 Zafirlukast (ICI-204219) Zafirlukast (ICI-204219) is an oral leukotriene receptor antagonist (LTRA), used to prevent asthma symptoms.
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Sci Rep, 2020, 10(1):17659
Biochem Biophys Res Commun, 2019, 520(1):35-40
S2959 LY255283 LY255283 is an antagonist of leukotriene B4 (LTB4) receptor (BLT2) that displaces [3H]LTB4 from its binding site on lung membranes with pKi of 7.0.
S4211 Montelukast Sodium Montelukast (MK-0476) selectively antagonizes leukotriene D4 (LTD4) by binding to it so that block the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1. Montelukast improves macroautophagy but not the chaperone-mediated autophagy pathway. Precipitations may form after reconstitution,solution is best fresh-prepared.
Cancer Immunol Immunother, 2021, 70(1):203-213
CU Digital Repository, 2021, N/A
G3 (Bethesda), 2020, 4;10(5):1585-1597
S5783 Montelukast Montelukast is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
Cancer Immunol Immunother, 2021, 70(1):203-213
CU Digital Repository, 2021, N/A
Oncol Rep, 2018, 40(2):902-908
S8126 MK571 MK571 (L660711) is a selective, orally active CysLT1 receptor(Cysteinyl leukotriene receptor) antagonist.
Neoplasia, 2021, 23(12):1227-1239
Res Vet Sci, 2021, 138:178-187
EMBO Mol Med, 2020, e10852
S3998 (+)-α-Lipoic acid (+)-α-Lipoic acid ((R)-(+)-α-Lipoic acid, α-Lipoic acid, Alpha-Lipoic acid), a physiological form of thioctic acid, is a strong antioxidant that relieves diabetic neuropathic symptoms. It shows superior antioxidative effects to its racemate. R(+)-α-lipoic acid is an essential cofactor of mitochondrial enzyme complexes. R(+)-α-lipoic acid inhibits NF-κB-dependent HIV-1 LTR activation.
S1633 Zafirlukast (ICI-204219) Zafirlukast (ICI-204219) is an oral leukotriene receptor antagonist (LTRA), used to prevent asthma symptoms.
Cell Chem Biol, 2021, S2451-9456(21)00213-0
Sci Rep, 2020, 10(1):17659
Biochem Biophys Res Commun, 2019, 520(1):35-40
S2959 LY255283 LY255283 is an antagonist of leukotriene B4 (LTB4) receptor (BLT2) that displaces [3H]LTB4 from its binding site on lung membranes with pKi of 7.0.
S4211 Montelukast Sodium Montelukast (MK-0476) selectively antagonizes leukotriene D4 (LTD4) by binding to it so that block the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1. Montelukast improves macroautophagy but not the chaperone-mediated autophagy pathway. Precipitations may form after reconstitution,solution is best fresh-prepared.
Cancer Immunol Immunother, 2021, 70(1):203-213
CU Digital Repository, 2021, N/A
G3 (Bethesda), 2020, 4;10(5):1585-1597
S5783 Montelukast Montelukast is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
Cancer Immunol Immunother, 2021, 70(1):203-213
CU Digital Repository, 2021, N/A
Oncol Rep, 2018, 40(2):902-908
S8126 MK571 MK571 (L660711) is a selective, orally active CysLT1 receptor(Cysteinyl leukotriene receptor) antagonist.
Neoplasia, 2021, 23(12):1227-1239
Res Vet Sci, 2021, 138:178-187
EMBO Mol Med, 2020, e10852